Clinical Trials Logo

Central Nervous System Diseases clinical trials

View clinical trials related to Central Nervous System Diseases.

Filter by:

NCT ID: NCT05738486 Recruiting - Dementia Clinical Trials

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

Start date: February 28, 2023
Phase: Phase 3
Study type: Interventional

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.

NCT ID: NCT05737420 Completed - Stroke Clinical Trials

Video-call Assisted Assessment of Acute Stroke in Addition to Stroke Severity Scales in a Prehospital Setting

Start date: July 6, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical services is feasible.

NCT ID: NCT05731986 Recruiting - Clinical trials for Cardiovascular Diseases

Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)

SCI
Start date: June 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effect of transcutaneous spinal cord stimulation on blood pressure in individuals with an acute spinal cord injury (within 30 days of injury). Blood pressure instability, specifically orthostatic hypotension (a drop in blood pressure when moving lying flat on your back to an upright position), appears early after the injury and often significantly interferes with participation in the critical rehabilitation time period. The main questions it aims to answer are: 1. Can optimal spinal stimulation increase blood pressure and resolve orthostatic symptoms (such as dizziness and nausea) when individuals undergo an orthostatic provocation (a sit-up test)? Optimal stimulation and sham stimulation (which is similar to a placebo treatment) will be compared. 2. What are the various spinal sites and stimulation parameters that can be used to increase and stabilize blood pressure to the normal range of 110-120 mmHg? Participants will undergo orthostatic tests (lying on a bed that starts out flat and then moved into an upright seated position by raising the head of bed by 90° and dropping the base of the bed by 90° from the knee) with optimal and sham stimulation, and their blood pressure measurements will be evaluated and compared.

NCT ID: NCT05725499 Recruiting - Clinical trials for Cardiovascular Diseases

The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)

SCI
Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This project will investigate the effect of spinal cord transcutaneous stimulation on blood pressure in individuals with a chronic spinal cord injury who experience blood pressure instability, specifically, orthostatic hypotension (a drop in blood pressure when moving from lying flat on your back to an upright position). The main questions it aims to answer are: 1. What are the various spinal sites and stimulation parameters that normalize and stabilize blood pressure during an orthostatic provocation (70 degrees tilt)? 2. Does training, i.e., exposure to repeated stimulation sessions, have an effect on blood pressure stability? Participants will undergo orthostatic tests (lying on a table that starts out flat, then tilts upward up to 70 degrees), with and without stimulation, and changes in their blood pressure will be evaluated.

NCT ID: NCT05722756 Completed - Clinical trials for Central Nervous System Diseases

The Effect of Craniosacral Therapy as Additive Procedure.

COREHNERV
Start date: January 1, 2014
Phase:
Study type: Observational

This observational, retrospective study has shown, that the addition of craniosacral therapy to the Vojta method has improved the effects of the therapy in 6 months follow-up period. The chance for improvement was 9.42 times higher in Vojta + craniosacral group compared to the group conducted only with Vojta method. The study results suggest that the craniosacral procedure should be considered as an additive regimen to the Vojta method in the therapy of children with central coordination disorders (CCD) . More data is still needed to improve the rehabilitation process in this group of patients.

NCT ID: NCT05652296 Recruiting - Clinical trials for Cerebrospinal; Disorder

External Ventricular Drainage Post-Market Clinical Follow-up Registry

Start date: March 3, 2023
Phase:
Study type: Observational

This post-market follow-up registry will capture clinical data specific to the safety and performance of the Integra External Ventricular Drainage Systems and Accessories.

NCT ID: NCT05590884 Recruiting - Clinical trials for Central Nervous System Diseases

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach. Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

NCT ID: NCT05527288 Completed - Alzheimer Disease Clinical Trials

A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

Start date: January 28, 2021
Phase: N/A
Study type: Interventional

This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.

NCT ID: NCT05522387 Active, not recruiting - Alzheimer Disease Clinical Trials

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.

NCT ID: NCT05508789 Recruiting - Alzheimer Disease Clinical Trials

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Start date: October 10, 2022
Phase: Phase 3
Study type: Interventional

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.